Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cue Biopharma (CUE) Interest & Investment Income (2018 - 2025)

Cue Biopharma's Interest & Investment Income history spans 8 years, with the latest figure at $281000.0 for Q3 2025.

  • For Q3 2025, Interest & Investment Income fell 18.08% year-over-year to $281000.0; the TTM value through Sep 2025 reached $939000.0, down 58.02%, while the annual FY2024 figure was $1.6 million, 39.05% down from the prior year.
  • Interest & Investment Income for Q3 2025 was $281000.0 at Cue Biopharma, up from $198000.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $905000.0 in Q4 2023 and bottomed at $3898.0 in Q4 2021.
  • The 5-year median for Interest & Investment Income is $281000.0 (2025), against an average of $319731.5.
  • The largest annual shift saw Interest & Investment Income crashed 95.0% in 2021 before it soared 16113.44% in 2022.
  • A 5-year view of Interest & Investment Income shows it stood at $3898.0 in 2021, then skyrocketed by 16113.44% to $632000.0 in 2022, then soared by 43.2% to $905000.0 in 2023, then tumbled by 67.96% to $290000.0 in 2024, then fell by 3.1% to $281000.0 in 2025.
  • Per Business Quant, the three most recent readings for CUE's Interest & Investment Income are $281000.0 (Q3 2025), $198000.0 (Q2 2025), and $170000.0 (Q1 2025).